JP Morgan analyst Arun Jayaram downgrades Ovintiv (NYSE:OVV) from Overweight to Neutral and lowers the price target from $59 to $53.
4 Analysts Assess OncoCyte: What You Need To Know
Analysts’ ratings for OncoCyte (NASDAQ:OCX) over the last quarter vary from bullish to bearish, as provided by 4…